#### **RESEARCH ARTICLE**



# **Extracellular vesicles carry transcriptional '***dark matter***' revealing tissue-specific information**



1 Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA

2Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA

3Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, USA

4Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, USA

5Department of Urology, Icahn School of Medicine at Mount Sinai, New York, USA

6DREAM Challenges

#### **Correspondence**

Dr. Navneet Dogra, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Email: [navneet.dogra@mssm.edu](mailto:navneet.dogra@mssm.edu)

Dr. Gustavo Stolovitzky, DREAM Challenges powered by Sage Bionetworks, Department of Biomedical Informatics, Department of Systems Biology, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY 10027, USA. Email: [gustavo.stolo@gmail.com](mailto:gustavo.stolo@gmail.com)

**Funding information**

NIH, Grant/Award Numbers: P20CA264076, R21 AG078848; IBM Research

#### **Abstract**

From eukaryotes to prokaryotes, all cells secrete extracellular vesicles (EVs) as part of their regular homeostasis, intercellular communication, and cargo disposal. Accumulating evidence suggests that small EVs carry functional small RNAs, potentially serving as extracellular messengers and liquid-biopsy markers. Yet, the complete transcriptomic landscape of EV-associated small RNAs during disease progression is poorly delineated due to critical limitations including the protocols used for sequencing, suboptimal alignment of short reads (20–50 nt), and uncharacterized genome annotations—often denoted as the '*dark matter*' of the genome. In this study, we investigate the EV-associated small unannotated RNAs that arise from endogenous genes and are part of the genomic '*dark matter*', which may play a key emerging role in regulating gene expression and translational mechanisms. To address this, we created a distinct small RNAseq dataset from human prostate cancer & benign tissues, and EVs derived from blood (pre- & post-prostatectomy), urine, and human prostate carcinoma epithelial cell line. We then developed an unsupervised databased bioinformatic pipeline that recognizes biologically relevant transcriptional signals irrespective of their genomic annotation. Using this approach, we discovered distinct EV-RNA expression patterns emerging from the un-annotated genomic regions (UGRs) of the transcriptomes associated with tissue-specific phenotypes. We have named these novel EV-associated small RNAs as '*EV-UGRs' or "EV-dark matter"*. Here, we demonstrate that EV-UGR gene expressions are downregulated by∼<sup>100</sup> fold (FDR *<* 0.05) in the circulating serum EVs from aggressive prostate cancer subjects. Remarkably, these EV-UGRs expression signatures were regained (upregulated) after radical prostatectomy in the same follow-up patients. Finally, we developed a stem-loop RT-qPCR assay that validated prostate cancer-specific EV-UGRs for selective fluid-based diagnostics. Overall, using an unsupervised data driven approach, we investigate the '*dark matter*' of EV-transcriptome and demonstrate that EV-UGRs carry tissue-specific Information that significantly alters pre- and post-prostatectomy in the prostate cancer patients. Although further validation in randomized clinical trials is required, this new class of EV-RNAs hold promise in liquid-biopsy by avoiding highly invasive biopsy procedures in prostate cancer.

#### **KEYWORDS**

biofluids, cancer, extracellular vesicles, liquid biopsy, RNA sequencing, small RNA

This is an open access article under the terms of the [Creative Commons Attribution](http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). *Journal of Extracellular Vesicles* published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.

Navneet Dogra, Tzu-Yi Chen and Edgar Gonzalez-Kozlova have contributed equally to the work.

## **I** | **INTRODUCTION**

Extracellular vesicles (EVs) are membrane-enclosed entities released by cells into their microenvironment and systemic circulation (Chen et al., [2022;](#page-18-0) Horstman et al., [2007;](#page-18-0) Johnstone et al., [1987;](#page-19-0) Skog et al., [2008;](#page-19-0) Soleymani et al., [2023;](#page-20-0) Trams et al., [1981;](#page-20-0) Valadi et al., [2007\)](#page-20-0). Recent evidence shows that EVs encapsulate small (∼13–200 nucleotides) functional RNAs (Bellingham et al., [2012;](#page-18-0) Crescitelli et al., [2021;](#page-18-0) Lässer et al., [2011;](#page-19-0) Skog et al., [2008;](#page-19-0) Valadi et al., [2007\)](#page-20-0), which can serve as extracellular messengers and induce recipient cells to change their behaviour (Krishn et al., [2020;](#page-19-0) Lässer et al., [2011;](#page-19-0) Sharma et al., [2019;](#page-19-0) Valadi et al., [2007\)](#page-20-0). Consequently, EVs and their RNA molecules are being recognized as a 'messenger of the cell'—a message written in nucleic acids (Bellingham et al., [2012;](#page-18-0) Eldh et al., [2012;](#page-18-0) Kalluri & LeBleu, [2020;](#page-19-0) Nakamya et al., [2022;](#page-19-0) Valadi et al., [2007\)](#page-20-0). These findings have resulted in major large-scale transcriptomic efforts (such as the NIH funded extracellular RNA communication consortium (ERCC)) to delineate the extracellular RNA (exRNA) from various cells, disease types, and biofluids (Das et al., [2019;](#page-18-0) Lucien et al., [2023;](#page-19-0) Murillo et al., [2019;](#page-19-0) Rozowsky et al., [2019;](#page-19-0) Srinivasan et al., [2019;](#page-20-0) Wei et al., [2017\)](#page-20-0). Subsequently, a large subset of EV-associated small RNAs (such as miRNA, tRNA, siRNA, snRNA, YRNA, snoRNA etc.) have been reported as potential biomarkers (Chand et al., [2021;](#page-18-0) Chen et al., [2023;](#page-18-0) Gaglani et al., [2021\)](#page-18-0), therapeutic mediators (Dogra & Stolovitzky, [2023;](#page-18-0) Lässer et al., [2011;](#page-19-0) Lee et al., [2018;](#page-19-0) Li et al., [2023\)](#page-19-0), and post-transcriptional regulators of gene regulation (Aday et al., [2021;](#page-18-0) Chen et al., [2018;](#page-18-0) Gaglani et al., [2021;](#page-18-0) Li et al., [2023\)](#page-19-0).

The human genome comprises <sup>∼</sup>2% of the well annotated protein coding exons (Harrow et al., [2012;](#page-18-0) Lander et al., [2001\)](#page-19-0). However, majority of the RNA is transcribed from outside of the exons and protein-coding regions (Harrow et al., [2012;](#page-18-0) Johnson et al., [2005;](#page-19-0) Kapranov et al., [2010\)](#page-19-0). These findings manifest the genomic complexity and present new paradigms of disease specificity and genomic regulation via un-annotated genomic regions (UGRs). Consequently, the UGRs, whose function and nomenclature remains poorly delineated, are denoted as the '*dark matter*' of the genome (Johnson et al., [2005;](#page-19-0) van Bakel et al., [2010\)](#page-20-0). Recent findings suggest that many RNA molecules which remain unannotated may play a critical role in regulation of gene expression (Bozgeyik, [2022;](#page-18-0) van Bakel et al., [2010\)](#page-20-0). Yet, the current RNA transcriptomic strategies apply a conventional reference-based approach, which is limited by their genomic annotations (Johnson et al., [2005\)](#page-19-0). Consequently, if the biologically relevant signals arise outside the regions of the genomic annotations, then they would be neglected during the bioinformatic analysis (Bozgeyik, [2022\)](#page-18-0). However, with major advances in next-generation sequencing technologies (Hallal et al., [2020;](#page-18-0) Srinivasan et al., [2019\)](#page-20-0) and novel computational tools (Abrams et al., [2019;](#page-18-0) Bellingham et al., [2012;](#page-18-0) Joo et al., [2019;](#page-19-0) Lu et al., [2018;](#page-19-0) Ritchie et al., [2015;](#page-19-0) Robinson et al., [2011\)](#page-19-0), it is now possible to study the complete transcriptome, providing an unparallel opportunity to assess not only the annotated genomic regions (AGRs) but also the largely uncharacterized UGRs. In this context, EVs carry small (∼13–200 nt) coding and non-coding RNAs (Chen et al., [2022\)](#page-18-0). Furthermore, recent transcriptomic efforts show that many EV-associated small RNAs arise from the non-coding, intergenic/intronic genomic regions (Johnson et al., [2005;](#page-19-0) Kapranov et al., [2010;](#page-19-0) Vojtech et al., [2014\)](#page-20-0). These important discoveries raise an important question, do EV-associated small un-annotated RNAs '*dark matter*' have implications in disease regulation and specificity?

In this study, we investigate the EV-associated small unannotated RNAs (EV-UGRs) that arise from endogenous genes and are part of the genomic '*dark matter*', which may play a key emerging role in regulating gene expression and translational mechanisms. To address this, we created a distinct small RNAseq dataset, followed by unsupervised data-based pipeline and strategy that recognizes biologically relevant transcriptional signals irrespective of their genomic annotation. Using this approach, we identified distinct EV-RNA expression patterns within UGRs, which are typically ignored during the conventional reference-based annotation approach (Dobin et al., [2013;](#page-18-0) Frankish et al., [2019\)](#page-18-0). Upon further investigation, we found that EVs carry distinct UGRs associated with tissue-specific phenotypes. We show that EV-UGRs gene expression is downregulated by∼100 folds (FDR*<*0.05) in the circulating serum EVs from aggressive prostate cancer subjects and is regained (upregulated) after prostatectomy, in the same follow-up patients. Next, we asked if EV-UGRs are restricted to inhouse datasets or can be recognized in external datasets. To address this, we investigated EV transcriptome in independent datasets including in-house (cell lines, prostate tissue, serum EVs, urine EVs, total *n* = 62) and external exRNA datasets (plasma EVs, *n* = 113 and cell lines and EVs, *n* = 18) and confirmed EV derived UGR and AGR expression profiles in cells and EVs (datasets described in Figure [1A–D,](#page-2-0) Figure S1). Finally, we selected top EV-UGRs, developed a custom stem-loop RT-qPCR assay, and validated their differential expression across different biofluids and tissue. Overall, we present an unsupervised data-driven approach that identifies biologically relevant transcriptional signals even when there is no genomic annotation. Using this approach, we demonstrate that EV-UGR signatures are novel small RNA candidates that carry tissue-specific RNA associated with advanced prostate cancer.

#### 2 | **METHODS**

#### **. Isolation of blood serum EVs using nanoDLD**

The EVs were isolated using these methods for results described in Figure [4.](#page-11-0) Before running biological samples, the integrated nanoDLD chips were first primed with bovine serum albumin, BSA. A F-100 microtight connector with a 1/16″ OD,∼2–4 cm long tube was fitted to the inlet port on the flow cell for this priming step. Additionally, a 1 mL syringe was prepared with a solution

<span id="page-2-0"></span>

**FIGURE**  Overview of experimental design and data analysis. (A) Number of samples and subtype composition of each dataset included in the analysis. (B) Sources of sample types. (C) Biofluid profiles of all samples. (D) Workflow of the EV-UGR analyses.

of 5% w/v BSA, (Sigma Aldrich) in a 1X phosphate buffer saline (Sigma Aldrich), the solution having been previously 0.02 μm filtered (Whatman). The syringe was attached to the tubing via a Luer Lock adapter. The excess DI water was then removed from the bump and zigzag outlet ports. The BSA syringe was set on the syringe pump and run at a fixed injection rate of 8  $\mu$ m min<sup>-1</sup> for *<sup>G</sup>* <sup>=</sup> 225 nm (*P*app <sup>∼</sup> 5 bar). For the first 5 min, the bump outlet is sealed with a microplug to ensure all drain TSVs are cleared of residual bubbles, then after 5 min the bump is left unsealed so fluid flows through both ports. After priming with BSA, a 1 mL syringe with the sample fluid (human serum) was attached to the inlet tubing. For the  $G = 225$  nm devices used, samples were 0.2 μm filtered. The tubing was purged, as in the bead case, until sample fluid exited the secondary port. The outlet ports were then cleared of any collected fluid, and the chip was allowed to run at 8 μL min<sup>−1</sup>. At this point, the sample run time clock was initiated, allowing sample to accumulate for 60 min. For the zigzag fluid, a F-100 microtight was fitted to the zigzag outlet port with a short piece of tubing (∼5 cm), the end of which was inserted into a 1.5 mL, tared centrifuge tube sealed with parafilm to collect zigzag fluid as it exited the device. Zigzag fluid was allowed to continuously collect for the entire run time. For the bump outlet, fluid was removed every 30 min manually, using a pipet, and collected in a separate, tared tube. Samples were weighed to determine the volume collected from the bump and zigzag reservoirs and then stored in a 4◦C fridge for analysis, typically within 24 h. EV isolation protocol with minor changes has also been published (Chen et al., [2022;](#page-18-0) Murillo et al., [2019;](#page-19-0) Smith et al., [2018;](#page-19-0) von Felden et al., [2021\)](#page-20-0).

## **. EV characterization with transmission electron microscopy (TEM)**

After differential ultracentrifugation, the PBS-resuspended isolate was evaluated with transmission electron microscopy (TEM) in a Hitachi 7000 transmission electron microscope operating at 80 kV. Briefly, equal volumes of the isolate and 3% Glutaraldehyde were mixed and kept at room temperature for 1 h. About 2 μL of osmium tetroxide was added to the mixture and incubated at room temperature for 1 h. The solution was then transferred to formvar coated TEM grids and observed under the electron microscope.

## **. Immuno-gold labeling of EVs**

Frozen EVs pellet was brought to room temperature. Equal volumes of EVs and 3% glutaraldehyde were mixed and kept at room temperature for 1 h. About 2 uL of EV pellet was transferred to formvar coated TEM grid (at least two grids were prepared for each sample). TEM grids were covered and dried at room temperature for 30 min. 100 uL drops of PBS were transferred to Parafilm. Dried TEM grids were carefully washed by transferring them on top of the PBS drops with the help of forceps (this step is repeated five times). The grid is transferred to a 100 ul drop of BSA (this step is repeated five times). Then, the grid is transferred on top of a 5 uL drop of primary antibody (CD81) in a blocking buffer for 30 min. Transfer the grid to a washing buffer/blocking buffer for 5 min (this step is repeated five times). A drop of 5 uL gold conjugated secondary antibody is transferred to the Parafilm. The grid is transferred (and covered) on top of the gold antibody drop for 30 min. Once completely incubated, the grid is washed by keeping on top of 100 uL PBS solution for 3 min (this step is repeated 10 times). Finally, contrast the EVs on the TEM grid with osmium tetraoxide for 10 min. The grid is ready for TEM imaging.

## **. Nanoparticle tracking analysis (size and zeta potential)**

To estimate the size and concentration of the isolate, we conducted nanoparticle tracking analysis (NTA) samples were diluted to approximately  $10^6$ – $10^7$  particles/mL in Millipore DI water. Particle concentration, size, and zeta potential were measured using ZetaView (Particle Metrix). Particle size and concentration were measured using the built-in EMV protocol and zeta potential was measured using the built-in EMV Zeta protocol.

#### **. Immuno-fluorescence co-localization analyses (Nanoview)**

Briefly, canonical tetraspanin exosome markers CD81, CD9, and CD63 against the EV surface are arrayed on silicon chips. EV suspensions are incubated with the chips overnight. After incubation, chips are washed with PBS on a shaker and air dried. Captured EVs are detected using Single Particle Interferometric Reflectance Imaging Sensor technology.

#### **. RNA extraction, small library preparation and next-generation sequencing**

Total RNA was extracted from the serum bump fraction of nanoDLD, serum EVs pellet from UC using the total EV RNA and Protein Isolation Kit (Invitrogen 4478545). 50 μL EVs from bump fraction, 100–200 uL serum EVs were resuspended in equal volume of ice-cold EV resuspension buffer. 2X denaturing solution was added to the final EVs solution on ice. Equal volume of acid-phenol:chloroform solution was added to each sample. The final solution was vortexed for 60 s and centrifuged at 10,000 x *g*. The top aqueous phase was carefully isolated without disturbing the lower organic phase. The top aqueous phase was transferred to the provided filter cartridge in collection tubes. Bound RNA was washed three times using the included wash solution. Finally, a preheated elution solution was used to elute the RNA in 100 μL volume. RNA was stored at −20◦C until it's RNA quality was assessed by bioanalyzer (Agilent 2100 Bioanalyzer, RNA 6000 Pico & small RNA Kit, Agilent Technologies).

cDNA Libraries were prepared for small RNAs using the SMARTer smRNA-seq Kit for Illumina (Takara Bio 635030). A total of 18 cycles of PCR were carried out to obtain a good yield of cDNA from tissue, cells, and EVs. Final library quality was verified with Qbit and bioanalyzer. Negative (no RNA) and positive controls provided expected results. Next-generation RNA sequencing was performed using a Novaseq (Illumina), 100 base pair, single-end reads at the Mount Sinai Genomics core.

#### **. Quantification and statistical analysis**

#### 2.7.1 Genome mapping

For quantification of gene expression, raw reads were aligned to the latest Ensembl GRCh38.p13 (GCA\_000001405.28) using bowtie aligner (version 2.5.4b). FeatureCounts was then used to map the aligned reads to the GENCODE v26 primary gene annotation, including transcripts corresponding to ncRNAs such as lncRNA, miRNA as well as protein-coding RNA. To maximize recovery and minimize the noise, multimapping reads were quantified up to  $m = 10$  and distributed using unique reads mapping distribution, as described in most recent best practices protocols.



## 2.7.2 Formal analysis

Data cleaning, filtering, and analysis were performed in R and under expressed genes or proteins with low or no counts across all samples of the similar phenotype were removed (at least one of the samples have CPM *>* 10). Normalization via trimmed mean of M-values in edgeR ensures library sizes of all samples are scaled properly to minimize the influences of external factors. The limma package, originally designed for microarray data, performs linear modelling on normally distributed data. Thus, to accommodate for the non independent mean-variance relationship of RNA-seq data, the voom function assigns a precision weight derived from the library size and normalization factor of each sample itself to convert the raw counts to log2-CPM values. The log2-transformed counts minimize the changes in variance as the count size increases. Prior to examining differential expressions, we performed unsupervised clustering of samples to evaluate the similarities and dissimilarities between samples as well as across phenotypes of interest using the prcomp package in R. The result is reflected in the PCA plots. Differentially expressed genes are discerned between (1) cell lines versus cell-line-derived EVs, and (2) Prostate cancer patient serum-derived EVs isolated using nanoDLD versus the EVs isolated using UC via the standard differential expression pipeline as illustrated in limma/edgeR packages. Results of the differentially expressed genes are represented in high-resolution heatmap as well as volcano plots made using pheatmap and ggplot2 packages.

## 2.7.3 Correlation analyses

Spearman Rho correlations were determined across cellular and EV genetic profiles as well as the proteomic profiles. Gene expressions were plotted in the *x*/*y* axis, where *x*/*y* axis are log2 (CPM), all RNA types were analysed.

## 2.7.4 | Biotype analysis

The gene biotype was recovered from the GTF annotation file for Ensembl GRCh38 (same as for alignment). Mapping resolution was kept as CDS with intron and exon annotation levels and combined to gene level when necessary. After differential expression quantification of gene biotype proportions, numbers and expression levels was taken into account. Thus, expressing gene biotype as (1) number of molecules per biotype (after lib. size adjustment) and (2) levels of expression using RPKM to adjust for gene/transcript length sizes.

## 2.7.5 | Characterization of UGRs

We identified UGR) using a moving-window average approach. First, a minimum distance between UGRs was set at 75 base pairs, reflecting the typical trimmed read length from our sequencing approach. Second, an expression threshold was established, requiring a minimum of 100 reads per UGR. These criteria were determined based on the minimum read coverage of annotated small RNA read clusters. The rationale for these choices is visually depicted in Figure [4A.](#page-11-0) This allowed us to capture genome-wide expression of clusters of RNAs in terms of UGRs, which typically overlapped known annotated RNA species (Figure [4A\)](#page-11-0). We defined three characterization metrics for UGRs: (1) the *complexity* of UGRs as a read tiling efficiency or coverage entropy measure, defined on a continuous scale of 0 (single single-read peak) to 1 (uniform distribution of reads); (2) peak coverage, the total number of reads supporting a UGR peak; (3) consensus sequence of the UGR peak. The set of all UGRs is the set of all accumulation loci of small RNA genes and their peak-coverage consensus sequences, constituting average de-novo assembled small RNA landscape with a standard count matrix. Overall, the UGRs have these general properties when combining both cellular and EV UGRs as a single set: (1) UGR length range between 10 and 10 kbp with a mean length of <sup>∼</sup>674 bp (Figure S1B); (2) The complexity of UGRs reveals peak-domination rather than uniform tiling (Figures [1C](#page-2-0) and [4\)](#page-11-0); (3) The number of unique reads per cluster and the number of reads in the peak divided by the total UGR length shows values of 30% (Figure [4D\)](#page-11-0). More importantly, UGRs capture previously unreported uncharacterized regions in the genome (Figure [4E–G\)](#page-11-0). Interestingly, the number of unique sequences detected in UGRs are smaller in unannotated regions due their smaller size and higher frequency of multimapped reads (Figure [4F\)](#page-11-0). Of note, UGR complexity further reveals that unannotated sequences are dominated by low complexity regions (Figure [4G\)](#page-11-0). Finally, we explored the gene biotype composition of annotated UGRs and show that the RNA landscape is composed of highly expressing noncoding RNAs, pseudogenes, VDJ variable regions, miRNAs, rRNAs, mtRNAs and protein coding genes (Figure [4H\)](#page-11-0). Finally, visually investigation of the expression patterns from EV-RNA using Integrative Genome Viewer (Figure S1).



## **. Trimming and mapping**

The SMARTerTM smRNA-Seq kit yields reads are flanked on the 5′ end by a leading triad of three bases from SMARTerTM template switching activity, and on the 3' end by the Illumina adapter and extra bases from the oligo dT (which are exactly 15 bp in length). We used Cutadapt33 to remove the first three nucleotides of all reads, specify the homopolymer adapter sequence AAAAAAAAAA to remove along with any sequence 3′ of it, and finally discard all reads that are smaller than 15 bp long after these filters are applied. The exact command used, as recommended by the (strand-sensitive) SMARTerTM smRNA-Seq kit, is cutadapt-m 15-u 3-a AAAAAAAAAA input.fastq*>*output.fastq. Therefore, our set of initial small RNAs are at least 15 bp long and are trimmed from positions 1–3 and also from the oligo dT 3' through to the adapter. Next, we performed alignment using bowtie -n1 m15 allowing multimapping reads up to 15 sites producing bam files containing all alignments. Then, we use multimap rescue to recover multimapping reads with up to 15 multimapping sites. Finally, these resulting alignments are clustered using a distance of at least 75 pb between clusters. Briefly, all analysis were done on R studio platform using R Version 3.5 and several packages including limma, edgeR, ggplot2, reshape, tidyverse, variancePartition, pheatmap, annotables, GenomicFeatures, GenomicRanges and doParallel.

## **. Construction of UGRs**

The UGRs are constructed based on two factors: (1) A minimum distance between the reads, and (2) an expression threshold or minimum number of reads. These parameters were set at 75 bp and 100 reads based on the trimmed read length from sequencing and an arbitrary limit for what we consider a positive detection of RNA amplification (Figure [3A,](#page-9-0) Figure S1).

## **. Profiling of UGRs using differential expression, correlations, and non-parametric statistical tests**

Here, we performed principal component analysis to evaluate the relationship between each sample UGR profile and variance analysis to determine the effect of demographics and technical variables in our experiments. Next, we used limma mixed linear models to perform differential expression analysis to estimate the significant (FDR *<* 5%) UGRs between EVs, cells, biofluids (serum, urine) and tissues (tumour and adjacent normal). To investigate whether exRNA and cellular UGRs capture (enclose) any key known RNA biotypes, we compared all genomic locus positions from UGRs and compared them to biotypes available in the ENSEMBL annotation for human genome version 38. The results were annotated and used for further comparisons between the samples. Two additional datasets were added as proof of principle for the properties of UGRs. The colorectal cancer and healthy patients samples, with cellular and exosomal parts were available for small RNAs. These samples were downloaded from <https://exrna-atlas.org/> and analysed through the same pipeline as our prostate cancer cohort. Next, we compared the results between differential expression between cells and EVs between prostate cancer and colorectal cancer cohort using spearman correlation and non-parametric Wilcoxon rank test. Finally, we compared UGR properties between all three datasets and the respective biotype overlaps between them using the statistical methods described above.

## **. Alignment to non-human species and microbiome**

To ensure that our EV-UGRs are not a contribution from microbiome-derived EVs, we use a prefiltering strategy to remove the microbiome contribution in our samples. We use a prefiltering strategy that consists of removing known sequencing artifacts, low quality reads and non-human sequences. This step removes the microbiome contribution in our samples. Prefiltering is a way of addressing the issue by removing those genes that are unlikely to be differentially expressed and so reduce the overall number of tests performed. We performed EV RNA alignment (pre- and post-filtering) to the non-human species (including microbiome). To this end, we aligned our EV transcriptome with microbiome database and found that <sup>∼</sup>10% of the EV transcriptome aligns with microbiome. We discovered that there is some contribution from the microbiome pre-filtering however only less than 1% of microbiome contributed post filtering. The post filtering data is used for EV-UGR detection in our study. The Figure S6 alignment of EV-RNA to non-human species and microbiome.



## **. XDEC RNA-Seq data deconvolution**

To deconvolute RNA-Seq data, we employed the XDec deconvolution algorithm, as implemented in the R script available at the following repository: XDec GitHub Repository. This method, developed by Oscar Murillo [\(odmurill@bcm.edu\)](mailto:odmurill@bcm.edu), is specifically designed for the deconvolution of complex RNA-Seq datasets, enabling the extraction of cargo type composition from bulk RNA-Seq data.

The following steps were undertaken using version 1.0.2 of the XDec algorithm (dated 2019-03-31):

- Data preparation: Raw RNA-Seq data was preprocessed to generate count matrices. Quality control checks were performed to ensure data integrity and eliminate low-quality reads.
- Normalization: The count matrices were normalized to account for differences in sequencing depth and other technical variations. Normalization was performed using established R packages to generate input suitable for the XDec algorithm.
- Running XDec algorithm: The XDec R script was executed according to the instructions provided in the repository. Key parameters were set to default values, and the script was run in an R environment (version 3.6.3 or later). The execution of the script involved the following sub-steps:
- Loading the RNA-Seq count matrices.
- Defining the reference profiles for known cargo types, which were obtained from XDEC github.
- Applying the deconvolution algorithm to estimate the proportions of different cargo types present in the bulk RNA-Seq samples.
- Post-processing and validation: The output from the XDec algorithm, which includes estimated cargo-type proportions, was further analysed. Validation of the deconvolution results was performed by comparing estimated proportions against known benchmarks from XDEC.
- Statistical analysis: To ensure robustness, statistical analyses were conducted on the deconvoluted data to assess the accuracy and reliability of the estimated cargo type proportions. This involved correlation analyses, principal component analysis (PCA), and other relevant statistical tests.

By utilizing the XDec deconvolution algorithm, we were able to gain insights into the cargo type composition of the RNA-Seq samples, thereby enhancing our understanding of the underlying biological processes and contributing to the overall goals of our study. The script and its comprehensive documentation facilitated the seamless application of this advanced deconvolution method to our data.

## **. Proteomics**

Each frozen pellet was homogenized by adding a pre-determined volume of lysis buffer (2% SDS/1X protease inhibitor/0.1 M Ambic). Enhanced BCA Protein Quantification assay was used to determine the total protein amount from each sample. Three technical replications were run per sample. Proteins from 20ul of EV lysates were separated from SDS using micro S-trap columns [\(http://www.protifi.com/s-trap/\)](http://www.protifi.com/s-trap/) and digested on column by trypsin. Resulting peptides were speedvac dried for LC–MS/MS analysis. Thermo Orbitrap Fusion Tribrid Mass Spectrometer was used for MS/MS analysis. Global normalization based on total number of ms/ms spectra (PSM) acquired was applied to the MS data. Spectral counts were used for semi-quantitative analysis to compare protein abundance among different samples.

Proteome Discoverer software (version 1.4) was used to search the acquired MS/MS data against a human protein database downloaded from the UniProt website. Positive identification was set at 5% protein FDR and 1% peptide FDR. Also, at least two unique spectra has to be identified per protein. Scaffold Proteome Software was used for post-database search processing. 422 proteins passed the filtering criteria and their expression profiles among these four samples were analysed to identify differentially expressed proteins. Qlucore Omics Explorer Statistical Software was used to perform appropriate statistical analysis.

## **. Vesiclepedia venn diagram**

The open-access Functional Enrichment Analysis Tool (FunRich) Version 3.1.3 was downloaded from [http://microvesicles.org/#.](http://microvesicles.org/%23) Within this tool, the most commonly reported extracellular vesicle protein list was downloaded. Using the Venn Diagram tool in FunRich, plots were generated comparing the number of overlapping proteins identified in our experimental proteomics data from UC, UCDG, and DLD with the most commonly reported EV protein list. The percent overlapping proteins was calculated for experimental data UC, UCDG, and DLD, respectively.

<span id="page-7-0"></span>

**FIGURE**  Characterization of the small EVs and their respective RNA cargo. (A) transmission electron microscopy (TEM) analyses of blood serum EVs from prostate cancer subjects. Scale bar is 100 nm. (B) Immunogold TEM analyses shows 6 nm gold-CD81 (a canonical marker for EVs) on the surface of vesicles. (C) Nanoparticle tracking analyses (NTA) present particles between the size of ~30–150 nm in diameter. Overall, ~2 × 10<sup>11</sup> particles/mL were detected in blood serum. (D) Immunofluorescence co-localization study (nanoview) for canonical tetraspanins show EVs are enriched with CD9, CD63, and CD81. (E) Immunofluorescence co-localization study shows EVs bound to the CD9 functionalized surface. (F) Minimum EV binding was observed when CD9 was not presented on the surface. (G & H) Capillary electrophoresis using pico chip for Bioanalyzer (Agilent) analyses revealed the size of small RNA in cells and EVs. (I) Capillary electrophoresis using small RNA chip for Bioanalyzer analyses revealed the size and distribution of small RNA in EVs.

#### **RESULTS**

#### **. Characterization of extracellular vesicles (EVs)**

In order to accurately characterize the EVs isolated in our study, we followed the minimal information for studies of extracellular vesicles (MISEV) (Lötvall et al., [2014;](#page-19-0) Théry et al., [2018;](#page-20-0) Welsh et al., [2024\)](#page-20-0) guidelines—a field-consensus rigor initiative of the International Society for Extracellular Vesicles (ISEV). Here, the EVs were observed under a high-resolution transmission electron microscopy (TEM), revealing a frequently reported (Lässer et al., [2011;](#page-19-0) Li et al., [2023\)](#page-19-0) round cup shaped morphology of <sup>∼</sup>30–150 nm particles (Figure 2A, Figure S2A–C). Immuno-gold TEM targeted to the small EV marker CD81 antibody attached to 6 nm colloidal gold particles displayed distribution of tetraspanin on the EV surface (Figure 2B). Nanoparticle tracking analyses (NTA) presented particles (∼2 × 10<sup>11</sup> particles/mL) between the size range of ~30–150 nm in diameter (Figures 2C, S2A–C). Next, we applied multi-colour immuno-fluorescence co-localization (Daaboul et al., [2016\)](#page-18-0) tool known as the ExoView Tetraspanin Kit, a protein microarray chip with antibodies against commonly expressed small EV tetraspanin proteins CD9, CD63 and CD81. We



quantified small EVs functionalized on immuno-stained chips to confirm the presence of canonical small EV markers CD9/63/81 on their surface (Figure [2D & E\)](#page-7-0). Figure [2E](#page-7-0) shows small EVs functionalized on CD9 immune-stained chips and negligible nonspecific binding, when no tetraspanins were functionalized the substrate (Figure [2F\)](#page-7-0). Taken together, small EVs isolated in our study display round, cup shaped morphology, of <sup>∼</sup>30–150 nm particles in diameter and displayed enrichment of canonical small EV tetraspanin markers (CD9/63/81) with minimum non-specific binding on the immuno-stained substrate. Furthermore, our recent publication conducted comprehensive characterization of EVs' proteo-transcriptome in separate studies (Chen et al., [2022;](#page-18-0) Li et al., [2023\)](#page-19-0). Next, we characterized the RNA from prostate tissue and patient matched serum derived EVs using capillary elec-trophoresis (Figure [2G & H\)](#page-7-0). We noticed that while the prostate tissue displayed small RNA and large ribosomal RNAs (18S and 28S) (Figure [2G\)](#page-7-0), the small EVs only enriched small RNA of *<*200 nucleotides (nt) (Figure [2H\)](#page-7-0). We confirmed these results using another analogous small RNA chip that allows for higher resolution separation of small RNAs ranging below <sup>∼</sup>200 nt, displaying two major peaks at <sup>∼</sup>66 nt and <sup>∼</sup>102 nt (Figure [2I\)](#page-7-0). Moreover, recent studies have confirmed that large RNAs (greater than <sup>∼</sup>3000 bp) are depleted in small EVs but are present in their donor cells and macrovesicles (Lässer et al., [2011;](#page-19-0) Valadi et al., [2007;](#page-20-0) Wei et al., [2017\)](#page-20-0). Overall, these results suggest that the RNA cargo of tissue and EVs are distinct. Tissues mostly displayed large ribosomal RNA (rRNA) (18S and 28S) and small RNA below <sup>∼</sup>200 nt, and small EVs did not display rRNA and enriched with small RNA below ~200 nt (Figure [2G](#page-7-0) & H). Within the small RNA landscape, EV-RNA displayed two major peaks at ~66 nt and <sup>∼</sup>102 nt (Figure [2I\)](#page-7-0), providing preliminary evidence of the different subtypes of small RNA. To address the different subtypes of proteins and RNAs in EVs, we proceeded with proteomics and total small RNA sequencing (discussed below).

## **. Proteomic and exRNA cargo type analyses of extracellular vesicles**

A common confounder of EV RNA and exRNA studies is that RNA in complex biological samples such as blood serum is associated with several extracellular particles, such as lipoproteins, Argonaute2 (AGO2), and diverse EVs (Arroyo et al., [2011;](#page-18-0) Turchinovich et al., [2011\)](#page-20-0). For this reason, it is important to assess the removal of non-EV RNA carriers such as lipoproteins (Driedonks et al., [2018;](#page-18-0) Nolte-'t Hoen et al., [2012\)](#page-19-0). To address this concern, we took two different approaches: (1) A proteomic analyses of EVs isolated using different technologies, followed by their comparison of MISEV 2023 recommended proteins (EV hallmarks and commonly co-isolated non-vesicular extracellular particles (NVEPs)) with our datasets; (2) We utilized ERCC developed exRNA XDEC toolkit to address the RNA cargo proportions from AGO2, lipoproteins, and small EVs in our isolations. Below we discuss these approaches.

1. Proteomics approach to delineate EV cargo: To uncover the ubiquitous and abundant EV proteins, we used an unbiased and quantitative proteomic approach of liquid chromatography coupled to high-resolution mass spectrometry.We have conducted these analyses on EVs isolated using ultracentrifugation (UC), UC in conjunction with density gradient (UC+DG), and nanoDLD (Figure [3A\)](#page-9-0). To ensure the reproducibility of proteomic analyses, we isolated EVs from 3 different human subjects and compared from three different methods (total *n* = 9). Principal components analysis (PCA) identified distinct clustering of EV-proteome by their method of isolation, demonstrating possible batch effects between the technologies (Figure [3B\)](#page-9-0). Venn diagram comparison uncovered that∼82% of the nanoDLD proteins were common with UC and UC+DG, while enriching for <sup>∼</sup>18% unique proteins (Figure [3C\)](#page-9-0). We then carefully followed the MISEV 2023 guidelines (Table 3. Protein content-based EV characterization) (Welsh et al., [2024\)](#page-20-0). We compared the curated list of MISEV 2023 recommended proteins (EV hallmarks and commonly co-isolated NVEPs) with our datasets (Figure [3D\)](#page-9-0). A high resolution heatmap shows that the lipoproteins (ApoA, ApoB, ApoC, ApoE, ApoH, and ApoL), which are commonly associated with NVEPs (such as HDL, LDL, vLDL, and Chylomicrons) were consistently depleted in the proteome of nanoDLD isolated EVs. Notably, the nanoDLD isolated EVs were enriched with MISEV recommended proteins (Welsh et al., [2024\)](#page-20-0), such as integrins (ITGA, ITGB, talin (TLN1)), transferrin receptor (TFR), heparan sulphate proteoglycans (PGBM, PGBM1, RELN), ESCRT protein (TRFE), and extracellular matrix proteins (Dermcidin/DCD, Filamin/FLNA, RET4). All three technologies used for EV isolation demonstrated ontologies-based pathways of Extracellular exosome (Figure [3E\)](#page-9-0). nanoDLD EVs were enriched with ontologies related to Extracellular vesicle, Extracellular organelle, Extracellular exosome (Figure [3E\)](#page-9-0). In contrast, UC and UC+DG also displayed presence of some blood microparticle pathway ontology (due to lipoprotein contribution). Notably, the blood microparticles associated ontology was absent in the nanoDLD EVs proteome. The cohort of depleted proteins in nanoDLD EVs was predominantly composed of lipoproteins and nuclear proteins. UC and UC+DG also displayed depletion of nuclear proteins and some lipoproteins. We did not detect many EV co-isolates (often used as negative controls for EVs) such as AGO2 proteins, calnexins (CANX), and Golgi matrix (GM130) protein in our EV samples from all three technologies. Finally, we utilized the large EV proteomic datasets from the Vesiclepedia database (a compilation of data from over <sup>∼</sup>1300 EV studies) (Kalra et al., [2012\)](#page-19-0). A comparison of our EV proteomic data with the Vesiclepedia database displayed an overlap of <sup>∼</sup>84% of the EVs proteins in our study relative to those in the Vesiclepedia (Figure [3F\)](#page-9-0). UC and UC+DG also showed an overlap (with Vesiclepedia) of 73% and 77%, respectively (Figure [3F\)](#page-9-0). These results confirmed that our EV isolation methods and

<span id="page-9-0"></span>



**FIGURE**  Mass spectrometry and exRNA cargo type analyses of EVs (A) Workflow: Serum EV isolation using different platforms: ultracentrifugation (UC), UC in conjunction with density gradient (UC+DG), and nanoDLD, followed by proteomics and EV-hallmark and pathway enrichment analyses. We isolated EVs from three different human subjects and compared between three different isolation methods (total  $n = 9$ ). (B) Principal components analysis (PCA) to identify possible batch effects between technologies. (C) Venn diagram comparison of common and unique EV proteins among three isolation technologies. (D) MISEV 2023 recommended EV, NVEP, and EVP hallmark analyses. Heatmap includes proteins from MISEV 2023 (Welsh, et al., JEV 2023, Table 3. Protein content-based EV characterization) recommended EV-hallmarks for EVs and NVEPs markers. Lipoproteins, and other common co-isolates, and EV-proteins are presented. E) Gene ontology pathway analyses is performed, and top pathway enrichment scores are compared. All three technologies used for EV isolation demonstrated ontologies-based pathways of Extracellular exosome. nanoDLD EVs were enriched with ontologies related to Extracellular vesicle, Extracellular organelle, Extracellular exosome (Figure 3E, Table S2). UC and UC+DG also displayed the presence of blood microparticle pathway ontology (due to lipoprotein contribution). Notably, the blood microparticles associated ontology was absent in the nanoDLD EVs proteome. (F) The top

proteomic analyses were consistent, relatively reproducible, and reliable compared to the other external studies present in the Vesiclepedia database and as per MISEV guidelines.

2. exRNA analyses to delineate EV cargo: A recent exRNA transcriptomic investigation from ERCC (Murillo et al., [2019\)](#page-19-0) investigated and compared extracellular RNA cargo types in <sup>∼</sup>5000 human samples using different isolation methods and biofluids. This independent analysis presented RNA cargo types associated with lipoproteins (HDL, LDL, and VLDL), argonaute proteins, and high & low-density vesicles (Murillo et al., [2019\)](#page-19-0). In this study, we utilized ERCC developed exRNA XDEC toolkit to address the RNA cargo proportions from AGO2, lipoproteins, and small EVs in our isolations (Figure [3G\)](#page-9-0). Total samples used for these analyses are: nanoDLD ( $n = 17$ ), UC ( $n = 14$ , urine  $= 7$ , serum  $= 7$ ), bulk tissue samples ( $n = 10$ , tumour  $= 5$ , normal = 5). Using the XDEC toolkit, we discovered that nanoDLD EVs enrich for RNA associated with high and low density vesicles (Figure [3G\)](#page-9-0). Notably, nanoDLD EVs did not show enrichment of AGO2 and lipoprotein-associated RNA (Figure [3G\)](#page-9-0). Similarly, UC EVs showed enrichment of RNA from high/low density vesicles with minimum contamination from lipoproteins. The RNA cargo type analyses for bulk prostate tissue showed relatively high enrichment of RNA associated with AGO2 proteins. Overall, the EVs isolated in our study enrich high and low density vesicles associated RNA with minimum contamination from AGO2 and lipoprotein-associated RNA. In contrast, prostate tissue displayed relatively high AGO2-associated RNA, confirming that AGO2 and lipoproteins-associated RNA are enriched in the cells and depleted in our EV isolation.

Taken together, we have conducted a comprehensive proteomic and exRNA analyses of EVs presented in this study. We demonstrate that nanoDLD isolated EVs are enriched with EV-associated, MISEV recommended protein, displayed ontologies of Extracellular exosome and Extracellular vesicle, and depleted lipoproteins. The cohort of depleted proteins in EVs was Argonaute2 (AGO2), calnexins (CANX), Golgi matrix (GM130), and nuclear proteins in our EV samples from all three technologies. Finally, to address the exRNA cargo type proportions of AGO proteins, lipoproteins, and small EVs in our isolations, we used ERCC developed exRNA XDEC toolkit. We found that nanoDLD EVs carry high and low density vesicles associated RNA with minimum contamination from AGO2 and lipoprotein-associated RNA. The fact that nanoDLD is able to deplete lipoproteins with great precision are reassuring primarily because nanoDLD is precisely designed as a microfluidic device that can sort, enrich <sup>∼</sup>100 nm particles, and remove large *<sup>&</sup>gt;* 200 nm (microfluidic channel width is 200 nm), and *<sup>&</sup>lt;*50 nm (including HDL, LDL, and AGO) with *>*90% accuracy. These finding have been reported in recent peer reviewed publications (Chen et al., [2022;](#page-18-0) Dogra & Stolovitzky, [2023;](#page-18-0) Kim et al., [2017;](#page-19-0) Murillo et al., [2019;](#page-19-0) Smith et al., [2018;](#page-19-0) Wunsch et al., [2016\)](#page-20-0). Figure S3A–D shows an overview of nanoDLD chip technology, where 'Bump<sup>&#</sup>x27; fraction sorts <sup>∼</sup>100 nm polystyrene particles, while 'zigzag<sup>&#</sup>x27; fraction contains <sup>∼</sup>25 nm</sup> polystyrene particles. Of note, <sup>∼</sup>25 nm beads do not concentrate with but <sup>∼</sup>95 nm beads concentrate <sup>∼</sup>35 folds with nanoDLD chip technology.

## **. Small RNA transcriptomic analyses reveal distinct un-annotated EV-RNAs**

Recently, EV-associated RNA transcriptomics have gained widespread interest for understanding their cargo, communication potential, and liquid-biopsy biomarkers (Bellingham et al., [2012;](#page-18-0) Chen et al., [2022;](#page-18-0) Murillo et al., [2019;](#page-19-0) Smith et al., [2018\)](#page-19-0). Yet, as of today, the complete (annotated and un-annotated) transcriptomic landscape of EVs remains poorly understood (Murillo et al., [2019;](#page-19-0) Rozowsky et al., [2019;](#page-19-0) von Felden et al., [2021\)](#page-20-0). Recent studies have identified critical limitations, including suboptimal alignment of short reads (20–50 nt) and missing genomic annotations (Murillo et al., [2019;](#page-19-0) von Felden et al., [2021\)](#page-20-0). To address these challenges, novel approaches for EV-transcriptomic analyses are needed, along with the urgent development of robust, reproducible, open-access and user-friendly protocols for EV diagnostics, quality control, and analysis. Here, we created an unsupervised data-based strategy that recognizes biologically relevant transcriptional signals irrespective of their genomic annotations (Methods & Figures [4A,](#page-11-0) S4 & S5). To quantify the small RNA expression patterns, we used '*de novo*' assembly and defined UGRs using the following criteria (Methods & Figure [4B–D\)](#page-11-0): (1) A minimum distance between the reads, and (2) an expression threshold. The expression properties of UGRs were defined as small read cluster (smRC) length (Figure [4B\)](#page-11-0), smRC complexity (Figure [4C\)](#page-11-0), smRC number of reads (Figure [4D\)](#page-11-0). The difference in length, complexity, and reads between annotated (blue) and unannotated UGRs (red) with statistical significance (FDR *<* 0.05) was computed with wilcoxon rank test (Figure  $4E-G$ ). Additionally, uncharacterized, or not annotated UGRs (red) also have lower number of unique reads and lower complexity compared to annotated regions (blue) (Figure [4G\)](#page-11-0). The annotated UGRs correspond not only to protein genes but to a wide spectrum of different genomic elements such as pseudogenes, lincRNAs, snoRNAs, rRNAs and other non-coding RNAs shown in blue (Figure [4H\)](#page-11-0). Additionally, the expression of previously uncharacterized UGRs (red) is also higher (Figure [4H\)](#page-11-0) than well studied miRNAs (blue) or protein coding genes (blue). Using this identification method, we were able to identify, quantify,

enriched proteins from our proteomics datasets are compared with Vesiclepedia database. (G) exRNA Atlas cargo type analyses to delineate cargo type proportions for EVs from Serum, urine, and tissue samples (bulk) are compared. Overall, the EVs isolated in our study enrich with high and low density vesicles associated RNA with minimum contribution from AGO2 and lipoprotein-associated RNA. Total samples used for this study: nanoDLD (*n* = 17), UC  $(n = 14, \text{urine} = 7, \text{serum} = 7)$ , bulk tissue samples  $(n = 10, \text{tumor} = 5, \text{normal} = 5)$ .

<span id="page-11-0"></span>



**FIGURE**  Characterization of UGRs/small read clusters (smRCs). (A) Schematic drawing of reads aligning on the genome highlighting 3 representative examples that help define UGRs and their properties. Left image or UGR/smRC2, has a minimum expression threshold representative of at least 100 reads aligned in a tight genomic region. This region is represented by a read pile up and very few surrounding reads besides the peak. Thus, showcasing a peak dominant UGR without uniform tiling or low complexity. Central image or UGR/smRC2 represents a region without any peaks or no peak dominance with a uniform tiling composition or high complexity. Additionally, between smRC1 and smRC2 there is a minimum distance of 75 base pairs arbitrarily defined by



and perform differential expression of UGRs expression profiles in human prostate cancer & benign tissues, and EVs derived from blood, urine, and cell culture media (discussed below). Finally, among the 38 different RNA biotypes that we investigated, UGRs were ranked 7th by expression (Figure [4H\)](#page-11-0), indicating the prevalence of highly expressed UGRs signals, yet ignored during analyses. A list of all 128 identified UGRs loci by their genomic location is provided in Table S1.

## **. Serum EV-RNA expressions are altered pre- and post-prostatectomy**

Next, we visually investigated the expression patterns from EV-RNAs (using Integrative Genome Viewer) (Robinson et al., [2011\)](#page-19-0). These analyses helped us identify unique expression patterns stemming from the UGRs. We detected UGR expression patterns at several regions of the genome, including intergenic and intronic regions in different chromosomes. Importantly, we discovered that circulating EV-UGRs have a significant association with tissue specific phenotypes, as demonstrated in the distinct example of transcriptional signal in chromosome 2 (Figure [5A\)](#page-13-0). The UGR expression patterns were present in the prostate normal (Figure [5A,](#page-13-0) green) and tumour tissue (Figure [5A,](#page-13-0) orange). Next, we discovered that the serum EV-UGRs were downregulated in the prostate cancer subjects pre-prostatectomy (Figure [5A,](#page-13-0) blue panel labelled as 'pre-prostatectomy', shows average expression from eight cancer subjects, inset shows individual expression from all eight subjects). Remarkably, the lost expression patterns reemerged once the same eight subjects underwent radical prostatectomy and∼2–3 months after had undetectable PSA (Figure [5A,](#page-13-0) red panel). Similarly, chromosome 6 (Figure [5B\)](#page-13-0) and chromosome 11 (Figure [5C\)](#page-13-0), displayed UGRs expression patterns from only partially annotated intergenic and intronic regions. All three select EV-UGRs were suppressed 'pre-prostatectomy' and re-emerged 'post-prostatectomy' (Figure [5A–C\)](#page-13-0). Notably, the prostate cancer subjects discussed above are the same matching subjects and their blood serum was collected pre-prostatectomy and were followed up∼2–3 months post-prostatectomy. The EVs isolation, RNA isolation, and sequencing was performed on all samples at the same time. Overall, EV-UGR signatures represent prostate cancer tissue-specific information in serum, which is downregulated during cancer but is re-emerged after prostatectomy in the matched cancer patients representing biologically relevant information. Of note, the human genome (Hg38) showed no or only partial annotation in regions of the UGR expression in human tissue, blood EVs, and in human prostate carcinoma epithelial cell line (22RV1) and their EVs (Figure [5A–F\)](#page-13-0).

## **. Prostate tissue and EVs derived from serum and urine carry distinct UGRs that span across the genome**

To examine whether different variables (patient age, PSA, Gleason score, tissue type, biofluid, and RNA origin) influence the UGR expression patterns, we profiled the variance associated with phenotypic features using mixed effect models (Gonzalez-Kozlova, [2022;](#page-18-0) Hoffman & Roussos, [2021;](#page-18-0) Ritchie et al., [2015\)](#page-19-0). We found that the origin of RNA was the main driver of variance in our data followed by patient age and PSA (Figure [6A\)](#page-14-0). Principal component analysis (PCA) resulted in the separation of the samples based on tissues, urine, and serum transcriptomes (Figure [6B\)](#page-14-0). Our differential expression analysis showed unique expression of cellular profiles compared with EVs (Figure [6C & D\)](#page-14-0). Next, we computed the spearman correlation between cellular and EV profiles, showing that EVs possess distinct (spearman rho =  $-0.07$ ) enrichment of UGRs (Figure [6E, F\)](#page-14-0). Finally, we present the top differentially expressed UGRs (in normal and tumor tissues, and EVs from serum and urine) that span across the genome and present in several chromosomes (Figure [6G\)](#page-14-0).

Next, to validate our in-house dataset and determine if UGRs are present in independent datasets, we used two NIH ERCC RNAseq datasets (Murillo et al., [2019\)](#page-19-0) of in vitro colorectal cancer (CRC) cells and plasma derived EV RNA (Figure [7A\)](#page-15-0). The PCA showed clear separation of UGR profiles across cellular, EV categories, normal and knockout (KO) cellular RNA (Figure [7A\)](#page-15-0). Next, we performed differential expression of the cellular and EVs components in this dataset identifying the UGRs with FDR *<* 1% (Figure [7B\)](#page-15-0). Then, we compared the overlap between all three datasets (Figure [7C\)](#page-15-0), showing that each dataset contained not only unique but also <sup>∼</sup>9000 shared UGRs (Figure [7C\)](#page-15-0). Interestingly, cellular UGRs had a higher expression than those found in EVs (Figure [7D\)](#page-15-0). Similar to the prostate cancer dataset described in Figure [6,](#page-14-0) in vitro CRC cellular UGRs were

the read size of our experiment that separates these two clusters. Right image or UGR/smRC7 represents a region with insufficient distance between a peak and a uniform tiling. Thus, both regions composed by the uniform tiling and the peak constitute the UGR 3, of moderate complexity. (B) The length of a UGR in our dataset varies from 14 to 10000 base pairs shows a function of density of all detected UGRs. (C) The distribution of complexity values for prostate cancer UGRs, has a median <sup>∼</sup>0.1 highlighting that the majority of UGRs are of low complexity. (D) Density function of the number of reads in the peak of a UGR divided by the total number of reads in the same UGR, shows a median of <sup>∼</sup>0.3. (E, F) The difference in length between annotated (blue) and unannotated UGRs (red) with statistical significance (FDR *<* 0.05) computed with wilcoxon rank test. Additionally, Uncharacterized, or not annotated UGRs (red) also have lower number of unique reads and lower complexity. (G) compared to annotated regions (blue). (H) The annotated UGRs correspond not only to protein genes but to a wide spectrum of different genomic elements such as pseudogenes, lincRNAs, snoRNAs, rRNAs and other non-coding RNAs shown in blue. Additionally, the expression of uncharacterized UGRs (red) is also higher than well studied miRNAs (blue) or protein coding genes (blue).

<span id="page-13-0"></span>



**FIGURE**  Visualization of selected UGRs in prostate cancer patients (tumor, normal, serum EVs pre- & post prostatectomy) and in human prostate carcinoma epithelial cell line (22RV1) and their EVs. Three distinct examples of UGRs identified at Chromosome 2, 6, and 11 visualized in Integrated Genome Browser. Expression patterns emanating from the un-annotated (A) and partially annotated (B, C) genomic regions from Chromosome 2, 6, and 11, respectively. EV-UGRs expression is downregulated pre-prostatectomy and upregulated post-prostatectomy in all three examples. Inset: UGR expression pattens from 8 prostate cancer (pre- and post-prostatectomy) subjects. (D) Human prostate carcinoma epithelial cell line (22RV1) and their EVs also show similar expression patterns in un-annotated (D) and partially annotated (E, F) genomic regions from Chromosome 2, 6, and 11, respectively. To ensure reproducibility, EVs are isolated using two different technologies nanoDLD (A–C) and UC (D–F). Reference sequence (Refseq) shows no annotation (A, D) or partial annotations (B, C, E, F) for the selected genomic regions.

<span id="page-14-0"></span>

**FIGURE**  Cellular and EVs profiles reveal distinct new UGRs. (A) Variance partition analyses shows that origin of RNA is the main driver of variance in our data followed by age and PSA. (B) Principal component analysis (PCA) resulted in the complete separation of the samples based on origin of RNA by tissue, urine, or serum. (C) The differential expression between cellular and EVs UGRs colored by EVs (blue) or cell (red). (D) MAplot showing the average expression in log2CPM scale colored by EVs (blue) or cell (red). (E) Spearman correlation between cells and EVs in log2CPM scale showing no correlation between either UGR expression. (F) The complexity of UGRs is shown in the y axis while the percentage of reads in the peak compared to the total reads is shown in x axis. These properties of cells or EVs show that the centers of density (black lines) align completely with their differential expression profiles (colors red for cells and blue for EVs) indicating that UGR properties also are defined by their RNA origin. (G) A selection of top UGRs for tumor, adjacent normal, urine or serum are shown in a heatmap. The annotation for samples is shown in the columns on the left of the plot for isolation type, tissue and RNA origin. The annotation on top of the heatmap indicates the average expression levels, the differential expression status (high in either tumor, adjacent normal, serum or urine) and the gene biotype for each UGR.

larger and contain a greater read proportion compared to EVs UGRs (FDR *<* 1%) (Figure [7E & F\)](#page-15-0). Additionally, EVs UGRs are less complex and have a greater read peak/totals proportion than their cellular counterparts (Figure [7G & H\)](#page-15-0). Finally, we investigated the composition of cellular and EV UGRs across our datasets, revealing that EV-UGRs carry larger proportions of unannotated genomic composition of small RNA and represent <sup>∼</sup>20%–40% of the whole transcriptome (Figure [7I\)](#page-15-0).

## **. EV-UGRs can be used a biomarker**

Most RNA-based studies apply conventional reference based approach and thus are limited to the annotated genomic regions (Joo et al., [2019;](#page-19-0) Rozowsky et al., [2019;](#page-19-0) Ziemann et al., [2016\)](#page-20-0). As a result, most extracellular RNAs used for liquid-biopsy studies are annotated (Kapranov et al., [2010;](#page-19-0) van Bakel et al., [2010;](#page-20-0) von Felden et al., [2021\)](#page-20-0). Here, to ascertain that EV-UGRs presented

<span id="page-15-0"></span>

FIGURE 7 Identification of UGRs in independent external datasets and development of a simple RT-qPCR assay. (A) Principal component profiles for CRC cell lines colored based on the wild or mutant (KRAS) status for either cells or EVs, showing a separation between each phenotype. (B) differential expression volcano plot between cells (red) and EVs (blue). (C) Overlap between UGRs from either cohort (Our PCA, EERC CRC cell lines and EERC health plasma patients. (D) The common UGRs between either cohort separated by their logFC based on cell/EVs comparison. (E) Comparison using Wilcoxon rank test between the lengths of UGRs from either cell (red) or EVs (blue) from different cohorts. (F) Comparison using Wilcoxon rank test between the percentage of unique reads from either cells (red) or EVs (blue). (G) Comparison using Wilcoxon rank test for the complexity values of either cells (red) or EVs (blue). (H) Comparison using Wilcoxon rank test for percentage of reads in the peak between cells (red) and EVs (blue). (I) Gene biotype composition between cells or EVs, showing that EVs contain a larger non coding and unannotated RNA footprint than cells. (J) RNAseq quantification of UGRs selected from differential expression pool. (K) RT-qPCR validation of select EV-UGRs from RNAseq data. No significant differences were found between technologies of EV isolation. Normal: normal tissue, Tumor: tumor tissue, Serum: serum EVs, Urine: urine EVs, Control: no template control. Following UGRs were tested for RT-qPCR: chr2:148881489-148881928, chr2:222918489-222918711, chr8:21329709-21329879.



in this study are not a biproduct of the library prep, alignment, or other computational biases, we selected top prostate tissuespecific UGRs, carefully designed targeted primers, and orthogonally validated their differential expression in our patient cohort by RNAseq (Figure [7J\)](#page-15-0) and developing a stem-loop RT-qPCR assay (Figure [7K\)](#page-15-0). We then compared RT-qPCR results with expression patterns from RNAseq data (Figure [7K\)](#page-15-0). The RT-qPCR results correlated with the RNAseq expression, discarding our hypothesis of alignment or other computational bias. RT-qPCR validation of select EV-UGRs from RNAseq data showed that no significant differences were found between technologies (nanoDLD and UC) of EV isolation (Figure [7K\)](#page-15-0). The three select UGRs for RT-qPCR validation were located in regions of chromosomes 2q, 8q (chr8:21329709-21329879, chr2:148881489- 148881928, chr2:222918489-222918711), and to the best of our knowledge, have not been studied before. Interestingly, some of the smRCs in our RNAseq analyses were selectively present in serum EVs but absent in the urine EVs (Figure [6G\)](#page-14-0) (this finding will be pursued in our future studies). Although preliminary, our analyses suggest that EVs-UGR RNAs may play a key emerging role in regulating gene expression, translational mechanisms, and can be used as biofluid-based biomarkers for minimally invasive (serum) or non-invasive (urine) diagnosis. Since, most previous studies have not investigated the '*dark matter*' uncharacterized genomic regions, there is little comparable data with a complete mapping of RNA species from the EVs. Regardless, these early findings contain major fluid-based diagnostic implications for many diseases, including cancers with precise measurements of up- or down-regulated EV-UGRs.

#### **DISCUSSION**

In this study, we investigate the EV-associated small unannotated RNAs (EV-UGRs) that arise from endogenous genes and are part of the genomic '*dark matter*', which may play a key emerging role in regulating gene expression and translational mechanisms. To address this, we created a distinct small RNAseq dataset, unsupervised bioinformatic pipeline, and detected biologically relevant transcriptional signals outside of their genomic annotation. We found that EVs carry distinct UGRs associated with tissue-specific phenotypes and that EV-UGR gene expressions are downregulated by <sup>∼</sup>100 fold (FDR *<sup>&</sup>lt;* 0.05) in the circulating serum EVs pre-prostatectomy from aggressive prostate cancer subjects. These select EV-UGR expression signatures were regained (upregulated) post-prostatectomy in the same follow-up patients. Taken together, our study suggests that small unannotated RNAs that arise from endogenous genes and are part of the genomic '*dark matter*', may play a key emerging role in regulating gene expression and translational mechanisms.

There are several possible explanations for the transcriptional activity that appears outside of annotations. These signals could be transcriptional 'noise', experimental artifacts, transposons, or previously undetected coding or noncoding genes (Bozgeyik, [2022;](#page-18-0) Johnson et al., [2005;](#page-19-0) Mcclintock, [1956;](#page-19-0) Rinke et al., [2013\)](#page-19-0). The fact that '*dark matter*' transcription has been observed by different groups (Bozgeyik, [2022;](#page-18-0) Johnson et al., [2005;](#page-19-0) Kapranov et al., [2010;](#page-19-0) Turchinovich et al., [2014;](#page-20-0) Vojtech et al., [2014\)](#page-20-0), on different platforms (van Bakel et al., [2010\)](#page-20-0), in different species (Huang et al., [2020;](#page-18-0) Kapranov et al., [2010;](#page-19-0) Rinke et al., [2013\)](#page-19-0), with similar outcomes suggests artifacts are not the dominant cause (Bozgeyik, [2022;](#page-18-0) van Bakel et al., [2010\)](#page-20-0). Furthermore, multiple lines of evidence suggest that more of the genome is transcribed than represented by current annotations (Johnson et al., [2005\)](#page-19-0). Importantly Turchinovich et al. [\(2014\)](#page-20-0) detected known gene loci, as well as unannotated loci and noted that <sup>∼</sup>35% of unannotated RNA reads did align to the Human Microbiome Project database—indicating that there is exogenous RNA sequencing in human plasma. In the context of EV-associated UGRs, Turchinovich (Huang et al., [2020;](#page-18-0) Turchinovich et al., [2014\)](#page-20-0), Vojtech et al. [\(2014\)](#page-20-0), and Huang et al. [\(2020\)](#page-18-0), have reported unannotated loci. To ensure that our EV-UGRs are not a contribution from microbiome-derived EVs, we use a prefiltering strategy that consists of removing known sequencing artifacts, low quality reads and non-human sequences (Figure S6) Alignment of EV-RNA to non-human species and microbiome). Alternatively, the UGR reads could have emerged due to the following reasons: (1) immature partial transcripts with introns not spliced out yet; (2) unannotated exons which might represent alternative splicing; (3) the repetitive regions or transposons are overexpressed, and such overpopulated regions need to be secreted out of the cell, which is something that EVs have been reported to conduct (Kutchy et al., [2020\)](#page-19-0). Finally, the data presented here continues to reinforce the hypothesis that the transcriptional landscape of EVs is complex and it is clear that in-depth biochemical experiments will be required to assess the biological relevance of '*dark matter*' transcripts. In line with above hypotheses, if the noncoding RNAs were dismissed as a mere transcriptional noise, gene regulation would not have been delineated in its current form of understanding (Elbashir et al., [2001;](#page-18-0) Fire et al., [1998\)](#page-18-0). A key remaining question is how do UGRs disseminate from cells to the EVs and what is their underlying function. Future studies along the lines described here will optimistically delineate their role in gene regulation and may enable noninvasive monitoring of cancer, neurodegenerative, and other disease biomarkers and identification of tissue specific UGRs RNA to potentially avoid unnecessary surgical procedures.

**18 of 21 | COGRA ET AL.** DOGRA ET AL.

## **. Study limitations**

There are limitations in the study design that prevent overly broad conclusions. First, the sample number is relatively small to control for all types of potential biases. Second, limited previous studies have characterized UGRs (von Felden et al., [2021\)](#page-20-0), therefore, there are limited comparable studies to date given the lack of complete mapping of RNA species from EVs as well as the characterization of UGRs in EVs. Third, the method used to characterize UGRs could differ across study groups, depending on their sequencing workflow and pipelines. However, this study stands as a demonstration of the applications and possibilities of utilizing 'de novo' assembly characterization for EV profiling to identify previously unannotated and novel RNA sequences. Indeed, we identified novel RNA sequences as potential novel biomarkers for prostate cancer. However, further validation and a larger cohort is needed to improve the robustness of the results presented here. Studies show that exRNA can be associated with EVs, AGO proteins, lipoproteins, and many other extracellular particles (Arroyo et al., [2011\)](#page-18-0). In our studies, we observed RNA in both nanoDLD isolated 'EV-enriched' and 'EV-depleted' fractions (Figure S3A). nanoDLD is one of the better technologies to precisely sort small EVs (∼50–200 nm) and deplete larger *<sup>&</sup>gt;*200 nm, and smaller *<sup>&</sup>lt;*50 nm particles, including AGO and lipoproteins with *>*90% accuracy. Our analyses of nanoDLD EV proteomics (Figure [3A–F\)](#page-9-0) and exRNA cargo type (Figure [3G\)](#page-9-0) analyses reassured us that the cargo type in our study is high or low density vesicles with minimum RNA contribution from AGO2 and other lipoproteins. Finally, although we have compared three different EV isolation technologies to reduce variability, it has been well accepted that isolation method may contribute dramatically on downstream molecular components from isolated EVs. Thus, caution must be observed while using different technologies for EV isolation. Overall, these data and methods provide novel metrics that can be used in future experiments to monitor a wide spectrum of disease and healthy phenotypes and to help establish non-invasive molecular tools for tracking the impact of unannotated and non-coding RNAs.

## **. Data and code availability**

Protocols for EV separation and characterization are provided with this manuscript and will be made available on EV TRACK [\(http://evtrack.org/\)](http://evtrack.org/) upon publication of the manuscript. Data reported in this paper has been shared by the lead contact. This paper does not report original code. The code used is available on [https://github.com/chentytina/22RV1\\_EV](https://github.com/chentytina/22RV1_EV) or upon request. RNA-seq data is available at <https://www.ncbi.nlm.nih.gov/geo/> can be searched with GEO number= GSE123736. Any additional information required to reanalyse the data reported in this paper is available from the lead contact upon request.

#### **AUTHOR CONTRIBUTIONS**

**Navneet Dogra**: Conceptualization (lead); data curation (lead); formal analysis (equal); funding acquisition (equal); investigation (lead); methodology (lead); supervision (lead); visualization (equal); writing – original draft (lead). **Tzu-Yi Chen**: Data curation (equal); formal analysis (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal). **Edgar Gonzalez-Kozlova**: Data curation (equal); formal analysis (equal); methodology (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal). **Rebecca Miceli**: Writing – original draft (equal); writing – review and editing (equal). **Carlos Cordon-Cardo**: Resources (equal); supervision (equal); writing – review and editing (equal). **Ashutosh K. Tewari**: Resources (equal); supervision (equal); writing – review and editing (equal). **Bojan Losic**: Formal analysis (equal); software (equal); visualization (equal). **Gustavo Stolovitzky**: Conceptualization (lead); funding acquisition (equal); investigation (equal); supervision (lead); writing – review and editing (equal).

#### **ACKNOWLEDGEMENTS**

We thank the team at IBM Watson Research Center for help with nanoDLD device. Especially at IBM, we thank Drs. Benjamin H. Wunsch, Sung-Cheol Kim, Stacey M. Gifford, Joshua T. Smith, Huan Hu, and Pablo Meyer for help with nanoDLD chip technology. We thank Dr. Bobby Sebra, Ms. Kimaada Allette, Ms. Rachel Weil, Ms. Kamala Bhatt, Ms. Reena Olson, and Dr. Susmita Sahoo for their valuable feedback. The authors thank Drs. Veronica Sanchez-Gonzalez and George Daaboul (NanoView Biosciences, Boston, MA) for helping with the Exoview analysis. Drs. Manuel Meyer and Emily Chen for help with mass spectrometry. Dr. Ronald E. Gordon for help with electron microscopy. The authors thank the office of Scientific Computing and the Genomics Core Facility at the Icahn School of Medicine at Mount Sinai (ISMMS) for providing computational resources and staff expertise, as well as the ISMMS Biorepository for providing some of the samples. We would like to acknowledge the following funding agencies and foundations: NIH P20CA264076 (N.D.), NIH R21 AGO78848 (N.D., E.G-K.)

#### **CONFLICT OF INTEREST STATEMENT**

The authors declare no conflicts of interest.

#### <span id="page-18-0"></span>**ORCID** *Navneet Dogra* **b** <https://orcid.org/0000-0002-4602-3991>

#### **REFERENCES**

- Abrams, Z. B., Johnson, T. S., Huang, K., Payne, P. R. O., & Coombes, K. (2019). A protocol to evaluate RNA sequencing normalization methods. *BMC Bioinformatics [Electronic Resource], 20(Suppl 24), 679. <https://doi.org/10.1186/s12859-019-3247-x>*
- Aday, S., Hazan-Halevy, I., Chamorro-Jorganes, A., Anwar, M., Goldsmith, M., Beazley-Long, N., Sahoo, S., Dogra, N., Sweaad, W., Catapano, F., Ozaki-Tan, S., Angelini, G. D., Madeddu, P., Benest, A. V., Peer, D., & Emanueli, C. (2021). Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro and in vivo. *Molecular therapy: The Journal of the American Society of Gene Therapy*, 29(7), 2239-2252. [https://doi.org/10.1016/](https://doi.org/10.1016/j.ymthe.2021.03.015) [j.ymthe.2021.03.015](https://doi.org/10.1016/j.ymthe.2021.03.015)
- Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., Tait, J. F., & Tewari, M. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proceedings of the National Academy of Sciences of the United States of America*, (12), 5003–5008. <https://doi.org/10.1073/pnas.1019055108>
- Bellingham, S. A., Coleman, B. M., & Hill, A. F. (2012). Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic Acids Research*, (21), 10937–10949. <https://doi.org/10.1093/nar/gks832>
- Bozgeyik, I. (2022). The dark matter of the human genome and its role in human cancers. *Gene*, 811, 146084. <https://doi.org/10.1016/j.gene.2021.146084>
- Chand, S., Gowen, A., Savine, M., Moore, D., Clark, A., Huynh, W., Wu, N., Odegaard, K., Weyrich, L., Bevins, R. A., Fox, H. S., Pendyala, G., & Yelamanchili, S. V. (2021). A comprehensive study to delineate the role of an extracellular vesicle-associated microRNA-29a in chronic methamphetamine use disorder. *Journal of Extracellular Vesicles*, (14), e12177. <https://doi.org/10.1002/jev2.12177>
- Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., Xia, H., Man, Q., Zhong, W., Antelo, L. F., Wu, B., Xiong, X., Liu, X., Guan, L., Li, T., … Guo, W. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*, (7718), 382–386. <https://doi.org/10.1038/s41586-018-0392-8>
- Chen, T. Y., Gonzalez-Kozlova, E., Soleymani, T., La Salvia, S., Kyprianou, N., Sahoo, S., Tewari, A. K., Cordon-Cardo, C., Stolovitzky, G., & Dogra, N. (2022). Extracellular vesicles carry distinct proteo-transcriptomic signatures that are different from their cancer cell of origin. *Iscience*, (6), 104414. [https://doi.org/](https://doi.org/10.1016/j.isci.2022.104414) [10.1016/j.isci.2022.104414](https://doi.org/10.1016/j.isci.2022.104414)
- Chen, T. Y., Mihalopoulos, M., Zuluaga, L., Rich, J., Ganta, T., Mehrazin, R., Tsao, C. K., Tewari, A., Gonzalez-Kozlova, E., Badani, K., Dogra, N., & Kyprianou, N. (2023). Clinical significance of extracellular vesicles in prostate and renal cancer. *International Journal of Molecular Sciences*, (19), 14713. [https://doi.org/](https://doi.org/10.3390/ijms241914713) [10.3390/ijms241914713](https://doi.org/10.3390/ijms241914713)
- Crescitelli, R., Lässer, C., & Lötvall, J. (2021). Isolation and characterization of extracellular vesicle subpopulations from tissues. *Nature Protocols*, (3), 1548–1580. <https://doi.org/10.1038/s41596-020-00466-1>
- Daaboul, G. G., Gagni, P., Benussi, L., Bettotti, P., Ciani, M., Cretich, M., Freedman, D. S., Ghidoni, R., Ozkumur, A. Y., Piotto, C., Prosperi, D., Santini, B., Ünlü, M. S., & Chiari, M. (2016). Digital detection of exosomes by interferometric imaging. Scientific Reports, 6, 37246. <https://doi.org/10.1038/srep37246>
- Das, S., Extracellular RNA Communication Consortium, Ansel, K. M., Bitzer, M., Breakefield, X. O., Charest, A., Galas, D. J., Gerstein, M. B., Gupta, M., Milosavljevic, A., McManus, M. T., Patel, T., Raffai, R. L., Rozowsky, J., Roth, M. E., Saugstad, J. A., Van Keuren-Jensen, K., Weaver, A. M., & Laurent, L. C. (2019). The extracellular RNA communication consortium: Establishing foundational knowledge and technologies for extracellular RNA research. *Cell*, (2), 231–242. <https://doi.org/10.1016/j.cell.2019.03.023>
- Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013). STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* (Oxford, England), 29(1), 15-21. <https://doi.org/10.1093/bioinformatics/bts635>
- Dogra, N., & Stolovitzky, A. G. (2023). Exosome vessels for delivery of molecular cargo. United States patent US 2020/0215201 A1.
- Driedonks, T. A. P., Nijen Twilhaar, M. K., & Nolte-'t Hoen, E. N. M. (2018). Technical approaches to reduce interference of fetal calf serum derived RNA in the analysis of extracellular vesicle RNA from cultured cells. *Journal of Extracellular Vesicles*, (1), 1552059. <https://doi.org/10.1080/20013078.2018.1552059>
- Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*, 411(6836), 494-498. <https://doi.org/10.1038/35078107>
- Eldh, M., Lötvall, J., Malmhäll, C., & Ekström, K. (2012). Importance of RNA isolation methods for analysis of exosomal RNA: Evaluation of different methods. *Molecular Immunology*, (4), 278–286. <https://doi.org/10.1016/j.molimm.2012.02.001>
- Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. *Nature*, 391(6669), 806-811. <https://doi.org/10.1038/35888>
- Frankish, A., Diekhans, M., Ferreira, A. M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J. M., Sisu, C., Wright, J., Armstrong, J., Barnes, I., Berry, A., Bignell, A., Carbonell Sala, S., Chrast, J., Cunningham, F., Di Domenico, T., Donaldson, S., Fiddes, I. T., … Flicek, P. (2019). GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Research*, 47(D1), D766-D773. <https://doi.org/10.1093/nar/gky955>
- Gaglani, S., Gonzalez-Kozlova, E., Lundon, D. J., Tewari, A. K., Dogra, N., & Kyprianou, N. (2021). Exosomes as a next-generation diagnostic and therapeutic tool in prostate cancer. *International Journal of Molecular Sciences*, 22(18), 10131. <https://doi.org/10.3390/ijms221810131>
- Gonzalez-Kozlova, E. E. (2022). Molecular profiling of liquid biopsies for precision oncology. Advances in Experimental Medicine and Biology, 1361, 235-247. [https://doi.org/10.1007/978-3-030-91836-1\\_13](https://doi.org/10.1007/978-3-030-91836-1_13)
- Hallal, S., Ebrahim Khani, S., Wei, H., Lee, M. Y. T., Sim, H. W., Sy, J., Shivalingam, B., Buckland, M. E., & Alexander-Kaufman, K. L. (2020). Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486-3p as a circulating biomarker that distinguishes glioblastoma from lower-grade astrocytoma patients. *International Journal of Molecular Sciences*, (14), 4954. <https://doi.org/10.3390/ijms21144954>
- Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., Barnes, I., Bignell, A., Boychenko, V., Hunt, T., Kay, M., Mukherjee, G., Rajan, J., Despacio-Reyes, G., Saunders, G., … Hubbard, T. J. (2012). GENCODE: The reference human genome annotation for The ENCODE project. *Genome Research*, 22(9), 1760-1774. <https://doi.org/10.1101/gr.135350.111>
- Hoffman, G. E., & Roussos, P. (2021). Dream: Powerful differential expression analysis for repeated measures designs. *Bioinformatics (Oxford, England)*, 37(2), 192–201. <https://doi.org/10.1093/bioinformatics/btaa687>
- Horstman, L. L., Jy, W., Minagar, A., Bidot, C. J., Jimenez, J. J., Alexander, J. S., & Ahn, Y. S. (2007). Cell-derived microparticles and exosomes in neuroinflammatory disorders. In *International review of neurobiology*, Vol. 79, pp. 227–268. Academic Press.
- Huang, Y., Cheng, L., Turchinovich, A., Mahairaki, V., Troncoso, J. C., Pletniková, O., Haughey, N. J., Vella, L. J., Hill, A. F., Zheng, L., & Witwer, K. W. (2020). Influence of species and processing parameters on recovery and content of brain tissue-derived extracellular vesicles. *Journal of Extracellular Vesicles*, (1), 1785746. <https://doi.org/10.1080/20013078.2020.1785746>

# <span id="page-19-0"></span>**20 of 21 | COGRA ET AL.** DOGRA ET AL.

- Johnson, J. M., Edwards, S., Shoemaker, D., & Schadt, E. E. (2005). Dark matter in the genome: Evidence of widespread transcription detected by microarray tiling experiments. *Trends in Genetics: TIG, 2I(2), 93-102.* <https://doi.org/10.1016/j.tig.2004.12.009>
- Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *The Journal of Biological Chemistry*, 262(19), 9412–9420.
- Joo, T., Choi, J. H., Lee, J. H., Park, S. E., Jeon, Y., Jung, S. H., & Woo, H. G. (2019). SEQprocess: A modularized and customizable pipeline framework for NGS processing in R package. *BMC Bioinformatics [Electronic Resource]*, (1), 90. <https://doi.org/10.1186/s12859-019-2676-x>
- Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. *Science (New York, N.Y.)*, 367(6478), eaau6977. [https://doi.](https://doi.org/10.1126/science.aau6977) [org/10.1126/science.aau6977](https://doi.org/10.1126/science.aau6977)
- Kalra, H., Simpson, R. J., Ji, H., Aikawa, E., Altevogt, P., Askenase, P., Bond, V. C., Borràs, F. E., Breakefield, X., Budnik, V., Buzas, E., Camussi, G., Clayton, A., Cocucci, E., Falcon-Perez, J. M., Gabrielsson, S., Gho, Y. S., Gupta, D., Harsha, H. C., … Mathivanan, S. (2012). Vesiclepedia: A compendium for extracellular vesicles with continuous community annotation. *PLoS Biology*, (12), e1001450. <https://doi.org/10.1371/journal.pbio.1001450>
- Kapranov, P., St Laurent, G., Raz, T., Ozsolak, F., Reynolds, C. P., Sorensen, P. H., Reaman, G., Milos, P., Arceci, R. J., Thompson, J. F., & Triche, T. J. (2010). The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. *BMC Biology*, , 149. [https://doi.org/10.1186/1741-](https://doi.org/10.1186/1741-7007-8-149) [7007-8-149](https://doi.org/10.1186/1741-7007-8-149)
- Kim, S. C., Wunsch, B. H., Hu, H., Smith, J. T., Austin, R. H., & Stolovitzky, G. (2017). Broken flow symmetry explains the dynamics of small particles in deterministic lateral displacement arrays. Proceedings of the National Academy of Sciences of the United States of America, 114(26), E5034-E5041. [https://doi.](https://doi.org/10.1073/pnas.1706645114) [org/10.1073/pnas.1706645114](https://doi.org/10.1073/pnas.1706645114)
- Krishn, S. R., Salem, I., Quaglia, F., Naranjo, N. M., Agarwal, E., Liu, Q., Sarker, S., Kopenhaver, J., McCue, P. A., Weinreb, P. H., Violette, S. M., Altieri, D. C., & Languino, L. R. (2020). The *α*v*β*6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis. *Journal of Extracellular Vesicles*, (1), 1763594. <https://doi.org/10.1080/20013078.2020.1763594>
- Kutchy, N. A., Peeples, E. S., Sil, S., Liao, K., Chivero, E. T., Hu, G., & Buch, S. (2020). Extracellular vesicles in viral infections of the nervous system. *Viruses*, (7), 700. <https://doi.org/10.3390/v12070700>
- Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R., & McEwan, P., … International Human Genome Sequencing Consortium. (2001). Initial sequencing and analysis of the human genome. *Nature*, 409(6822), 860–921. <https://doi.org/10.1038/35057062>
- Lässer, C., Alikhani, V. S., Ekström, K., Eldh, M., Paredes, P. T., Bossios, A., Sjöstrand, M., Gabrielsson, S., Lötvall, J., & Valadi, H. (2011). Human saliva, plasma and breast milk exosomes contain RNA: Uptake by macrophages. *Journal of Translational Medicine*, 9, 9. <https://doi.org/10.1186/1479-5876-9-9>
- Lee, S. H., Shin, S. M., Zhong, P., Kim, H. T., Kim, D. I., Kim, J. M., Heo,W. D., Kim, D.W., Yeo, C. Y., Kim, C. H., & Liu, Q. S. (2018). Reciprocal control of excitatory synapse numbers by Wnt and Wnt inhibitor PRR7 secreted on exosomes. *Nature Communications*, 9(1), 3434. <https://doi.org/10.1038/s41467-018-05858-2>
- Li, X., La Salvia, S., Liang, Y., Adamiak, M., Kohlbrenner, E., Jeong, D., Chepurko, E., Ceholski, D., Lopez-Gordo, E., Yoon, S., Mathiyalagan, P., Agarwal, N., Jha, D., Lodha, S., Daaboul, G., Phan, A., Raisinghani, N., Zhang, S., Zangi, L., … Sahoo, S. (2023). Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart. *Circulation*, (5), 405–425. <https://doi.org/10.1161/CIRCULATIONAHA.122.063759>
- Lötvall, J., Hill, A. F., Hochberg, F., Buzás, E. I., Di Vizio, D., Gardiner, C., Gho, Y. S., Kurochkin, I. V., Mathivanan, S., Quesenberry, P., Sahoo, S., Tahara, H., Wauben, M. H., Witwer, K. W., & Théry, C. (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. *Journal of Extracellular Vesicles*, 3, 26913. <https://doi.org/10.3402/jev.v3.26913>
- Lu, Y., Baras, A. S., & Halushka, M. K. (2018). miRge 2.0 for comprehensive analysis of microRNA sequencing data. *BMC Bioinformatics [Electronic Resource]*, (1), 275. <https://doi.org/10.1186/s12859-018-2287-y>
- Lucien, F., Gustafson, D., Lenassi, M., Li, B., Teske, J. J., Boilard, E., von Hohenberg, K. C., Falcón-Perez, J. M., Gualerzi, A., Reale, A., Jones, J. C., Lässer, C., Lawson, C., Nazarenko, I., O'Driscoll, L., Pink, R., Siljander, P. R., Soekmadji, C., Hendrix, A., … Nieuwland, R. (2023). MIBlood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research. Journal of Extracellular Vesicles, 12(12), e12385. <https://doi.org/10.1002/jev2.12385>
- Mcclintock, B. (1956). Controlling elements and the gene. *Cold Spring Harbor Symposia on Quantitative Biology*, 21, 197-216. [https://doi.org/10.1101/sqb.1956.021.](https://doi.org/10.1101/sqb.1956.021.01.017) [01.017](https://doi.org/10.1101/sqb.1956.021.01.017)
- Murillo, O. D., Thistlethwaite, W., Rozowsky, J., Subramanian, S. L., Lucero, R., Shah, N., Jackson, A. R., Srinivasan, S., Chung, A., Laurent, C. D., Kitchen, R. R., Galeev, T., Warrell, J., Diao, J. A., Welsh, J. A., Hanspers, K., Riutta, A., Burgstaller-Muehlbacher, S., Shah, R. V., … Milosavljevic, A. (2019). exRNA atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids. *Cell*, 177(2), 463-477.e15. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.cell.2019.02.018) [cell.2019.02.018](https://doi.org/10.1016/j.cell.2019.02.018)
- Nakamya, M. F., Sil, S., Buch, S., & Hakami, R. M. (2022). Mitochondrial extracellular vesicles in CNS disorders: New frontiers in understanding the neurological disorders of the brain. *Frontiers in Molecular Biosciences*, 9, 840364. <https://doi.org/10.3389/fmolb.2022.840364>
- Nolte-'t Hoen, E. N., Buermans, H. P., Waasdorp, M., Stoorvogel, W., Wauben, M. H., & 't Hoen, P. A. (2012). Deep sequencing of RNA from immune cellderived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. *Nucleic Acids Research*, (18), 9272–9285. <https://doi.org/10.1093/nar/gks658>
- Rinke, C., Schwientek, P., Sczyrba, A., Ivanova, N. N., Anderson, I. J., Cheng, J. F., Darling, A., Malfatti, S., Swan, B. K., Gies, E. A., Dodsworth, J. A., Hedlund, B. P., Tsiamis, G., Sievert, S. M., Liu, W. T., Eisen, J. A., Hallam, S. J., Kyrpides, N. C., Stepanauskas, R., … Woyke, T. (2013). Insights into the phylogeny and coding potential of microbial dark matter. *Nature*, 499(7459), 431-437. <https://doi.org/10.1038/nature12352>
- Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, (7), e47. <https://doi.org/10.1093/nar/gkv007>
- Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011). Integrative genomics viewer. *Nature Biotechnology*, (1), 24–26. <https://doi.org/10.1038/nbt.1754>
- Rozowsky, J., Kitchen, R. R., Park, J. J., Galeev, T. R., Diao, J., Warrell, J., Thistlethwaite, W., Subramanian, S. L., Milosavljevic, A., & Gerstein, M. (2019). exceRpt: A comprehensive analytic platform for extracellular RNA profiling. *Cell Systems*, (4), 352–357.e3. <https://doi.org/10.1016/j.cels.2019.03.004>
- Sharma, P., Mesci, P., Carromeu, C., McClatchy, D. R., Schiapparelli, L., Yates, J. R. 3rd, Muotri, A. R., & Cline, H. T. (2019). Exosomes regulate neurogenesis and circuit assembly. Proceedings of the National Academy of Sciences of the United States of America, 116(32), 16086-16094. <https://doi.org/10.1073/pnas.1902513116>
- Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Sena-Esteves, M., Curry, W. T. Jr, Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nature Cell Biology*, (12), 1470– 1476. <https://doi.org/10.1038/ncb1800>
- Smith, J. T., Wunsch, B. H., Dogra, N., Ahsen, M. E., Lee, K., Yadav, K. K., Weil, R., Pereira, M. A., Patel, J. V., Duch, E. A., Papalia, J. M., Lofaro, M. F., Gupta, M., Tewari, A. K., Cordon-Cardo, C., Stolovitzky, G., & Gifford, S. M. (2018). Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. *Lab on a Chip*, (24), 3913–3925. <https://doi.org/10.1039/c8lc01017j>

<span id="page-20-0"></span>

- Soleymani, T., Chen, T. Y., Gonzalez-Kozlova, E., & Dogra, N. (2023). The human neurosecretome: Extracellular vesicles and particles (EVPs) of the brain for intercellular communication, therapy, and liquid-biopsy applications. *Frontiers in Molecular Biosciences*, 10, 1156821. [https://doi.org/10.3389/fmolb.2023.](https://doi.org/10.3389/fmolb.2023.1156821) [1156821](https://doi.org/10.3389/fmolb.2023.1156821)
- Srinivasan, S., Yeri, A., Cheah, P. S., Chung, A., Danielson, K., De Hoff, P., Filant, J., Laurent, C. D., Laurent, L. D., Magee, R., Moeller, C., Murthy, V. L., Nejad, P., Paul, A., Rigoutsos, I., Rodosthenous, R., Shah, R. V., Simonson, B., To, C., … Laurent, L. C. (2019). Small RNA sequencing across diverse biofluids identifies optimal methods for exRNA isolation. *Cell*, 177(2), 446-462.e16. <https://doi.org/10.1016/j.cell.2019.03.024>
- Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G. K., Ayre, D. C., Bach, J. M., Bachurski, D., Baharvand, H., Balaj, L., Baldacchino, S., Bauer, N. N., Baxter, A. A., Bebawy, M., … Zuba-Surma, E. K. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*, (1), 1535750. <https://doi.org/10.1080/20013078.2018.1535750>
- Trams, E. G., Lauter, C. J., Salem, N. Jr, & Heine, U. (1981). Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. *Biochimica et Biophysica Acta*, (1), 63–70. [https://doi.org/10.1016/0005-2736\(81\)90512-5](https://doi.org/10.1016/0005-2736(81)90512-5)
- Turchinovich, A., Surowy, H., Serva, A., Zapatka, M., Lichter, P., & Burwinkel, B. (2014). Capture and Amplification by Tailing and Switching (CATS). An ultrasensitive ligation-independent method for generation of DNA libraries for deep sequencing from picogram amounts of DNA and RNA. *RNA Biology*, (7), 817–828. <https://doi.org/10.4161/rna.29304>
- Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011). Characterization of extracellular circulating microRNA. *Nucleic Acids Research*, (16), 7223– 7233. <https://doi.org/10.1093/nar/gkr254>
- Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature Cell Biology*, (6), 654–659. <https://doi.org/10.1038/ncb1596>
- van Bakel, H., Nislow, C., Blencowe, B. J., & Hughes, T. R. (2010). Most "dark matter" transcripts are associated with known genes. *PLoS Biology*, (5), e1000371. <https://doi.org/10.1371/journal.pbio.1000371>
- Vojtech, L., Woo, S., Hughes, S., Levy, C., Ballweber, L., Sauteraud, R. P., Strobl, J., Westerberg, K., Gottardo, R., Tewari, M., & Hladik, F. (2014). Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions. *Nucleic Acids Research*, (11), 7290–7304. <https://doi.org/10.1093/nar/gku347>
- von Felden, J., Garcia-Lezana, T., Dogra, N., Gonzalez-Kozlova, E., Ahsen, M. E., Craig, A., Gifford, S., Wunsch, B., Smith, J. T., Kim, S., Diaz, J. E. L., Chen, X., Labgaa, I., Haber, P., Olsen, R., Han, D., Restrepo, P., D'Avola, D., Hernandez-Meza, G., … Villanueva, A. (2021). Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, gutjnl-2021-325036. Advance online publication. [https://doi.org/10.1136/gutjnl-2021-](https://doi.org/10.1136/gutjnl-2021-325036) [325036](https://doi.org/10.1136/gutjnl-2021-325036)
- Wei, Z., Batagov, A. O., Schinelli, S., Wang, J., Wang, Y., El Fatimy, R., Rabinovsky, R., Balaj, L., Chen, C. C., Hochberg, F., Carter, B., Breakefield, X. O., & Krichevsky, A. M. (2017). Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. *Nature Communications*, (1), 1145. <https://doi.org/10.1038/s41467-017-01196-x>
- Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H., Di Vizio, D., Driedonks, T. A. P., Erdbrügger, U., Falcon-Perez, J. M., Fu, Q. L., Hill, A. F., Lenassi, M., Lim, S. K., Mahoney, M. G., Mohanty, S., Möller, A., Nieuwland, R., … Witwer, K. W. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *Journal of Extracellular Vesicles*, (2), e12404. [https://doi.org/10.1002/](https://doi.org/10.1002/jev2.12404) [jev2.12404](https://doi.org/10.1002/jev2.12404)
- Wunsch, B. H., Smith, J. T., Gifford, S. M., Wang, C., Brink, M., Bruce, R. L., Austin, R. H., Stolovitzky, G., & Astier, Y. (2016). Nanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20 nm. *Nature Nanotechnology*, (11), 936–940. <https://doi.org/10.1038/nnano.2016.134>
- Ziemann, M., Kaspi, A., & El-Osta, A. (2016). Evaluation of microRNA alignment techniques. *RNA (New York, N.Y.)*, 22(8), 1120-1138. [https://doi.org/10.1261/](https://doi.org/10.1261/rna.055509.115) [rna.055509.115](https://doi.org/10.1261/rna.055509.115)

#### **SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Dogra, N., Chen, T.-Y., Gonzalez-Kozlova, E., Miceli, R., Cordon-Cardo, C., Tewari, A. K., Losic, B., & Stolovitzky, G. (2024). Extracellular vesicles carry transcriptional '*dark matter*' revealing tissue-specific information. *Journal of Extracellular Vesicles*, 13, e12481. <https://doi.org/10.1002/jev2.12481>